BOSTON SCIENTIFIC CORP 8-K

What Happened
Boston Scientific Corporation announced on May 18, 2026 (press release) that it entered an investment agreement with privately held MiRus LLC. On May 15, 2026 the company paid $1.5 billion (in addition to a prior $100 million payment) to acquire non‑voting common equity representing 33.75% of MiRus on a fully diluted basis, plus an exclusive Call Option to acquire a new subsidiary (“TAVR‑Structural Heart NewCo”) holding MiRus’s Siegel TAVR System assets for up to $3.0 billion in additional cash if certain clinical and regulatory milestones are met. The Siegel TAVR System has an FDA investigational device exemption to run the STAR randomized controlled trial aimed at supporting a future PMA.

Key Details

• Initial cash consideration: $1.5 billion paid May 15, 2026 (plus a prior $100 million payment).
• Equity stake: 33.75% of MiRus (non‑voting common equity, fully diluted).
• Option to acquire TAVR business: exclusive Call Option to buy TAVR‑Structural Heart NewCo for up to $3.0 billion upon achievement of specified milestones; MiRus may also receive future sales‑based payments if the Call Option is exercised and closes.
• Additional optional purchase: if the Call Option is exercised, Boston Scientific has an exclusive option to acquire mitral and tricuspid replacement valve assets for an extra payment. If the Call Option is not exercised or does not close, Boston Scientific’s MiRus stake may be forfeited, reduced by ~75%, or exchanged for an interest in NewCo depending on circumstances.

Why It Matters
This is a strategic, near‑term move into transcatheter aortic valve replacement (TAVR) technology: Boston Scientific paid $1.6 billion cash to date ($1.5B + prior $100M) for a significant minority stake and secured an option to obtain full ownership of the TAVR business for up to $3.0B contingent on clinical/regulatory progress. For investors, the material points are the immediate cash outflow, the potential future contingent payments, and the dependence on clinical trial and FDA milestones (the STAR trial and a future PMA). Execution risks noted in the filing include clinical trial outcomes, regulatory approvals, timing of option exercise, and possible post‑closing integration or business disruptions — all of which will affect whether Boston Scientific ultimately acquires the TAVR assets and the timing of any related revenue or costs.